Addex Therapeutics Ltd ADXN

Morningstar Rating
CHF 0.02 −0.00 (9.40%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ADXN is trading at a LOCK|?Cg%j premium.
Price
CHF 0.02
Fair Value
LOCK|<>m&m<?
Uncertainty
LOCK|jH ^g$!
1-Star Price
LOCK|<!wT%r&
5-Star Price
LOCK|cT>B?<?
Economic Moat
LOCK|nX
Capital Allocation
—

Trading Information

Previous Close Price
CHF 0.02
Day Range
CHF 0.02–0.02
52-Week Range
CHF 0.02–0.07
Bid/Ask
CHF 0.02 / CHF 0.02
Shares Outstanding
210.29M
Market Cap
CHF 4.46M
Volume/Avg
173,670 / 858,036

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
83.46
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
3

Valuation

Metric
ADXN
Price/Earnings (Normalized)
—
Price/Book Value
1.42
Price/Sales
83.46
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
ADXN
Quick Ratio
0.59
Current Ratio
0.76
Interest Coverage
−2,159.87
Quick Ratio
ADXN

Profitability

Metric
ADXN
Return on Assets (Normalized)
−112.74%
Return on Equity (Normalized)
−148.35%
Return on Invested Capital (Normalized)
−146.45%
Return on Assets
ADXN

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|g?@Tz@tLOCK|%n%$$126B
Moderna Inc
MRNA
LOCK|<Y?t$x$LOCK|%zs$90B
Regeneron Pharmaceuticals Inc
REGN
LOCK|%KxNpD<LOCK|Sp?p>$80B
argenx SE ADR
ARGX
LOCK|PX<<>XLOCK|zyR$53B
BeOne Medicines Ltd ADR
ONC
LOCK|YZGy%#!LOCK|FY>$41B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|@!Cn<@BLOCK|>xdd@$30B
Royalty Pharma PLC Class A
RPRX
LOCK|@G%Y@vlLOCK|#b&n$26B
Incyte Corp
INCY
LOCK|R^!%c#LOCK|$l$23B
BioNTech SE ADR
BNTX
LOCK|!xyH#$yLOCK|@D$22B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|f^BZtn!LOCK|PXP$14B

Sponsor Center